TheStreet Quant Ratings rates VIVUS, Inc. (NASDAQ:VVUS) as a sell. The company’s weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, generally disappointing historical performance in the stock itself and generally high debt management risk. VIVUS, Inc. (NASDAQ:VVUS) stock opened at $9.11 in last trading session, and currently trading at $9.16, trading in the range of $9.08 – $9.26. The stock showed a negative weekly performance of -3.51%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares currently trading at $6.31 on last trade day, by increasing 4.13%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) 52 week range is $4.05 – $11.00. Company’s market capitalization is $1.38 billion.
Ariad Pharmaceuticals (NASDAQ:ARIA) had its target price boosted by UBS AG from $2.50 to $7.50 in a report issued on Monday, Stock Ratings Network.com reports. They currently have a neutral rating on the stock. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock down -0.30% and currently trading at $6.72. The EPS of the stock remained -1.46. Company’s market capitalization is $1.25 billion.
Mannkind announces tentative date of FDA advisory committee review of AFREZZA. Co announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA is tentatively scheduled on April 1, 2014 to review MannKind’s New Drug Application for AFREZZA nhalation Powder. MannKind Corporation (NASDAQ:MNKD) stock opened at $6.69 in last trading session and currently trading at $6.34. The 52 week range of the stock is $2.34 – $8.70 and the day range was $5.90 – $6.69.